Stay updated on Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial
Sign up to get notified when there's something new on the Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial page.

Latest updates to the Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page now displays the completed HIV-1 dose-ranging study record, including its treatment arms, eligibility criteria, locations, and reported outcome measures, instead of an access-denied error.SummaryDifference100%

- Check15 days agoChange DetectedThe site’s footer revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide notice says NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” under Executive Order 14434 and links to updates and FAQs.SummaryDifference1%

- Check29 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer revision identifier advanced from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check43 days agoChange DetectedA 403 Forbidden message and a Home link appear in place of the study content, indicating the study record could not be displayed.SummaryDifference0.5%

Stay in the know with updates to Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial page.